Product Design & Development

ZymoGenetics shares rise, new medical chief named

By The Associated Press
Thursday, June 11, 2009
 Share
[-] Text [+]  
Loading...

ZymoGenetics shares rise, new medical chief named

NEW YORK (AP) — Shares of ZymoGenetics Inc. rose Thursday after the company said it named Dr. Eleanor L. Ramos chief medical officer to fill the position left by Dr. Nicole Onetto.

Shares rose 15 cents, or 3.3 percent, to $4.76 in midday trading. The stock has traded between $2.06 and $9.25 over the last 52 weeks.

Onetto resigned June 5, shortly after the company announced it would lay off 32 percent of its staff, or 161 employees. The cuts come as the drug developer looks to cut research and development programs and seeks to outsource activities.

Ramos joined ZymoGenetics in January of 2007 as vice president of clinical research, immunology and inflammation and became Vice President of clinical development in 2008. Prior to joining ZymoGenetics, she worked at Bristol-Myers Squibb and the Immune Tolerance Network.

ADVERTISEMENT

Seattle-based ZymoGenetics sells Recothrom, which is used to control bleeding during surgical procedures. It is also developing a potential hepatitis C drug with Bristol-Myers Squibb as part of a deal worth up to $1.12 billion.

JOIN THE DISCUSSION
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

At Issue

Beta Products & The Human Guinea Pig
Mike Willshaw, Radius Creative
My Garbage Blanket
Anna Wells, Editor, IMPO
A Quick Fix
Meaghan Ziemba, Associate Editor, PD&D

Quick Links

Site Sponsors


Most Viewed

Videos & Webcasts

Cannon vs. Skull 3/17/2010
Schmit Prototypes builds a canon powerful enough to blow your brains out.   Continue
Dynamic Structures Digital Prototyping 3/17/2010
When designing their structures, Dynamic Structures uses Audtodesk Inventor to go beyond 3D design.   Continue
Augmenting Reality 3/17/2010
The new technology makes driving more safe and convenient by enhancing the driver’s site.   Continue